|
KMID : 0043320220450090597
|
|
Archives of Pharmacal Research
2022 Volume.45 No. 9 p.597 ~ p.617
|
|
|
Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer
|
|
Kwon Mi-Jeong
|
|
|
Abstract
|
|
|
|
Globally, breast cancer is the most common malignancy in women. Substantial efforts have been made to develop novel therapies, including targeted therapies and immunotherapies, for patients with breast cancer who do not respond to standard therapies. Consequently, new targeted therapies, such as cyclin-dependent kinase 4 and 6 inhibitors, poly (ADP-ribose) polymerase inhibitors, phosphoinositide 3-kinase inhibitor, and antibody?drug conjugates targeting human epidermal growth factor receptor 2 or trophoblast cell surface antigen-2, and immune checkpoint inhibitor targeting programmed cell death-1, have been developed and are now in clinical use. However, only some patients have benefited from these novel therapies; therefore, the identification and validation of reliable or more accurate biomarkers for predicting responses to these agents remain a major challenge. This review summarizes the currently available predictive biomarkers for breast cancer and describes recent efforts undertaken to identify potential predictive markers for molecularly targeted therapies and immune checkpoint inhibitors.
|
|
|
KEYWORD
|
|
|
Breast cancer, Predictive biomarker, Molecularly targeted therapies, Immune checkpoint inhibitors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|